Iradimed (IRMD) risk factors, FY2024 10-K

Risks Relating to Our Business and Financial Condition

1. 01Our financial performance is significantly dependent on a limited number of products, and disruptions in our ability to sell these products may have a material adverse effect on our business
2. 02Our current revenue and profitability are significantly dependent on the sale of the MRidium 3860+ MRI compatible IV infusion pump system, the 3880 MRI compatible patient vital signs monitoring system (both Class II medical devices) and the ongoing sale of related disposables and services
3. 03Our continued success depends on the integrity of our supply chain and unaffiliated third-party suppliers for certain of our raw materials and components, the disruption of which could negatively impact our business
4. 04A cyber security incident or failure to protect our information technology infrastructure could be disruptive to our business, compromise confidential data, cause reputation harm, adversely affect our business and operating results, subject us to litigation and federal and state governmental inquiries
5. 05The manufacture of our products requires strict adherence to regulatory requirements governing medical devices and if we or our suppliers encounter problems our business could suffer
6. 06Our markets are very competitive, and we sell certain of our products in a mature market
7. 07We manufacture and store our products at a single facility in Florida
8. 08rendered inoperable or inaccessible due to political, social or economic upheaval or due to natural or other disasters, it
9. 09Our ability to sell our products to U.S. hospitals, acute care facilities and outpatient imaging centers depends in part on our relationships with IDNs and GPOs
10. 10The lengthy sales cycle for medical devices could delay our sales
11. 11Because we rely on distributors to sell our products outside of the U.S., our revenues could decline if our existing distributors do not continue to purchase products from us or if our relationship with any of these distributors is terminated
12. 12If we do not successfully develop and commercialize enhanced products or new products that remain competitive, we could lose revenue opportunities and customers, and our ability to achieve growth would be impaired
13. 13We are highly dependent on our founder, Chairman of the Board of Directors, President and Chief Executive Officer, Roger Susi
14. 14We may be unable to scale our operations successfully
15. 15We engage in related party transactions, which result in a conflict of interest involving our management
16. 16The environment in which we operate makes it difficult to accurately forecast our business performance
17. 17Changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could adversely affect our results
18. 18risks and challenges to our operations that could give rise to legal or regulatory action, damage our reputation or otherwise materially harm of our business

Risks Related to Our Industry

1. 19We are subject to substantial government regulation that is subject to change and could force us to make modifications to how we develop, manufacture, market, and price our products
2. 20If we fail to obtain, or experience significant delays in obtaining, FDA clearances or other necessary approvals to commercially distribute new products, our ability to maintain profitability or grow will suffer
3. 21We are subject to risks associated with doing business outside of the U.S
4. 22We may incur product liability losses or become subject to other lawsuits related to our products, business, and insurance coverage could be inadequate or unavailable to cover these losses
5. 23Our products or product types, or MR imaging could be subject to negative publicity, which could have a material adverse effect on our financial position and results of operations and could cause the market value of our common stock to decline
6. 24U.S. healthcare policy and changes thereto, including the Patient Protection and Affordable Care Act, may have a material adverse effect on our financial condition and results of operations
7. 25legislation to limit and/or increase transparency of interactions with healthcare providers, pursuant to which we are required by law to disclose payments and other transfers of value to healthcare providers licensed by certain states
8. 26We are subject to healthcare fraud and abuse regulations that could result in significant liability, require us to change our business practices and restrict our operations in the future
9. 27We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws

Risks Relating to our Intellectual Property

1. 28Our success depends on our ability to protect our intellectual property, unpatented trade secrets, know-how, confidential and proprietary information, and technology
2. 29There is a risk that our trade secrets and other confidential and proprietary information could have been, or could, in the future, be shared by any of our former employees with, and be used to the benefit of, any company that competes with us
3. 30There can be no assurance of timely patent review and approval that would minimize competition and allow us to generate sufficient revenues
4. 31We may become involved in patent litigation or other intellectual property proceedings relating to our current and future product clearances, which could result in liability for damages or delay or stop our development and commercialization efforts

Risks Related to Ownership of Our Common Stock

1. 32Our common stock price has been and will likely continue to be subject to significant fluctuations and volatility, and you may be unable to sell your shares at a fair price, or at all
2. 33Any use of capital to repurchase shares of our common stock, need to or choice to raise future capital, the election to continue, reduce or cease to pay a regular cash dividend, could have a material adverse effect on our stock price and our business
3. 34The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain executive management and qualified Board members
4. 35Roger Susi, who serves as our Chairman of the Board of Directors, President and Chief Executive Officer, owns a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder approval
5. 36Our business practices are more visible as a public company, and this could impact our competitive environment and risk of potential litigation or involvement in securities class action litigation that could adversely affect our business and could subject us to significant liabilities
6. 37If securities or industry analysts fail to initiate research coverage of our stock, downgrade our stock, or discontinue coverage, our trading volume might be reduced, and our stock price could decline
7. 38Our charter documents and Delaware law have provisions that may discourage an acquisition of us by others and may prevent attempts by our stockholders to replace or remove our current management